National Cancer Institute Program Project Applications for the Years 2023, 2024, and 2025 (P01 Clinical Trial Optional)
ID: 344891Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/344891

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-059.html
Timeline
    Description

    The National Institutes of Health, through the National Cancer Institute (NCI), invites applications for the National Cancer Institute Program Project Applications (P01) for the years 2023, 2024, and 2025, with an emphasis on integrated cancer research. Applicants are required to propose a program that includes at least three interrelated research projects and an Administrative Core, all centered around a common scientific theme related to cancer biology, prevention, diagnosis, treatment, or control. This initiative aims to enhance collaborative efforts in cancer research, addressing critical areas that contribute to the understanding and treatment of cancer. Interested applicants must adhere to the application guidelines outlined in the SF424 Application Guide, with key submission deadlines starting from April 25, 2023, and the final close date set for May 7, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-23-059.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-059-Full-Announcement.html
    PAR-23-059.html
    The Department of Health and Human Services, through the National Cancer Institute (NCI), has released a Funding Opportunity Announcement (FOA) inviting grant applications for investigator-initiated Program Project Applications (P01) for 2023-2025. This initiative supports integrated cancer research programs focusing on diverse areas such as cancer biology, prevention, diagnosis, treatment, and control. Each application must include at least three interrelated research projects alongside an Administrative Core, all centered around a unified scientific goal. Key dates include the earliest submission date of April 25, 2023, with subsequent deadlines throughout 2024 and 2025. Eligible applicants range from higher education institutions to non-profits and government entities, with a noted encouragement for underrepresented groups in research. The funding is anticipated to vary based on NIH appropriations, with project periods extending up to five years. The FOA emphasizes adherence to application guidelines outlined in the SF424 Application Guide and stresses the importance of a Data Management and Sharing Plan. Review criteria include scientific significance, innovation, approach, and the qualifications of investigators. This structured initiative aims to accelerate collaborative cancer research, enhancing the understanding and treatment of cancer through coordinated efforts among multiple disciplines.
    Similar Opportunities
    NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced the NCI Small Grants Program for Cancer Research (R03) for the years 2023 to 2025. This funding opportunity is designed to support small-scale research projects on cancer that can be completed within a two-year timeframe and with limited resources, including pilot studies, secondary data analyses, and the development of research methodologies or technologies. Grants of up to $50,000 per year are available to a wide range of eligible applicants, including higher education institutions, nonprofits, and various community organizations. Interested parties should submit their applications electronically via Grants.gov, with the first submission deadline having been January 22, 2023, and subsequent deadlines continuing through 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NIA Program Project Applications (P01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIA Program Project Grants (P01 Clinical Trial Optional), aimed at advancing research in aging-related scientific areas. Applicants must propose at least three interrelated research projects centered around a common theme, along with an administrative core to manage the initiative, addressing topics such as genetics, biology, and Alzheimer’s disease. This funding opportunity is crucial for fostering collaborative research efforts among established scientists and early-career researchers, ultimately contributing to the understanding and improvement of public health concerning aging. Interested organizations must submit their applications by September 7, 2025, and can find additional details and requirements at the provided NIH link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    NINDS Program Project Grant (P01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Neurological Disorders and Stroke (NINDS), is offering the Program Project Grant (P01) to support innovative, collaborative research addressing significant scientific questions within its mission. This grant encourages multi-disciplinary projects that are interdependent, allowing for greater scientific advancements than individual efforts, and applications may include clinical trials, although those focused on intervention effectiveness should seek different funding opportunities. Eligible applicants include higher education institutions, nonprofits, and governmental entities, with funding of up to $1 million in direct costs per year available for a maximum project period of five years. Interested parties should consult with NINDS staff early in the proposal process, with the application submission period opening on April 25, 2024, and due by May 25, 2024; for further inquiries, contact grantsinfo@nih.gov.
    NIDA Program Project Grant Applications (P01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is inviting applications for Program Project Grants (P01 Clinical Trial Optional) aimed at fostering collaborative, multidisciplinary research on substance use disorders. Applicants must propose a minimum of three interrelated research projects that demonstrate scientific and administrative synergy under a unifying theme, addressing critical issues such as neuroscience, genetics, behavior, prevention, treatment, and health services related to substance use. This funding opportunity emphasizes inclusivity, requiring a Plan for Enhancing Diverse Perspectives (PEDP) and encouraging participation from underrepresented groups, with a maximum project duration of five years. Interested applicants can find more information and submit inquiries via grantsinfo@nih.gov, with applications due by January 7, 2026.
    NCI Small Grants Program for Cancer Research (NCI Omnibus) (R03 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the NCI Small Grants Program for Cancer Research (R03), aimed at supporting short-term cancer research projects that require limited resources. This funding opportunity encourages diverse research efforts, including pilot studies, secondary data analyses, and the development of research methodologies, with a maximum budget of $50,000 per year for projects lasting up to two years. The program is designed to address significant knowledge gaps in cancer research and is open to a wide range of applicants, including public, private, and foreign entities. Interested parties should note that the application period opens on January 24, 2025, with a submission deadline of February 24, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Allergy and Infectious Diseases (NIAID), is inviting applications for the Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed) grant. This funding opportunity aims to support multi-project research initiatives that focus on infectious, immunologic, and allergic diseases, requiring each application to include at least two synergistic research projects and an administrative core, all centered around a common theme. The initiative is crucial for advancing research in areas such as the biology and pathogenesis of infectious microbes, immune system mechanisms, and the development of vaccines and therapeutics. Interested applicants must submit their proposals electronically via Grants.gov by September 7, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. The funding amount is not limited but should reflect the actual needs of the proposed projects.
    Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2024, 2025, and 2026 (P50 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for Specialized Programs of Research Excellence (SPOREs) in Human Cancers, aimed at supporting innovative translational research from 2024 to 2026. This initiative invites applications for P50 Research Center Grants that focus on enhancing cancer prevention, early detection, diagnosis, and treatment, particularly for organ-specific cancers or related groups, with a requirement for at least one clinical trial component in each application. The program is crucial for advancing cancer research and addressing health disparities, with funding available up to $1,400,000 in direct costs per year over a five-year project period. Interested applicants can find more information and application guidelines at the NIH website and should direct inquiries to grantsinfo@nih.gov, with the application deadline set for September 25, 2026.
    National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the National Cancer Institute (NCI) for investigator-initiated early phase clinical trials focused on cancer treatment and diagnosis, specifically under the R01 Research Project Grant mechanism (PAR-24-085). This initiative invites research proposals for Phase 0, I, and II clinical trials that align with the missions of various NCI programs, while explicitly excluding Phase III trials. The program aims to advance cancer research by assessing novel therapeutic and diagnostic interventions, improving imaging technologies, and exploring treatment combinations, with applications encouraged from a diverse range of eligible organizations, including educational institutions and non-profits. Interested applicants should note that the submission deadlines begin on January 5, 2024, with the opportunity closing on January 8, 2027. For further details, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-085.html.
    Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering the Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) to support investigator-initiated clinical trials aimed at reducing the burden of cancer. This funding opportunity focuses on enhancing early detection, prevention, healthcare delivery, and survivorship improvements, explicitly excluding studies related to cancer diagnosis or oncologic therapies. Eligible applicants include a diverse range of organizations such as higher education institutions, nonprofits, and tribal organizations, with applications due by 5:00 PM local time on January 5, 2024, and a maximum project period of five years. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the program's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-072.html.
    Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Modular R01s in Cancer Control and Population Sciences grant, aimed at advancing research in cancer management and outcomes. This funding opportunity supports innovative projects focusing on statistical methods, epidemiology, digital health, and cancer survivorship, with a particular emphasis on addressing significant challenges in cancer research. Eligible applicants include a diverse range of organizations, such as higher education institutions and community-based organizations, with no cost-sharing requirement, and the maximum funding limit is set at $250,000 per year for a project duration of up to five years. Interested parties should note that applications are due starting January 5, 2025, and can find further details by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the official announcement at https://grants.nih.gov/grants/guide/pa-files/PA-25-172.html.